However, if BCR-ABL1 fusion occurred after a long period of Ph− MPN phase, such a clone might harbor other genetic aberrations, due to selective pressure from other drug treatments, for example, hydroxyurea, leading to an unfavorable treatment response. This evidence concerns the gene BCR and myeloproliferative neoplasm.